首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal PIK3CA Antibody

  • 中文名: PIK3CA抗体
  • 别    名: MCM; CWS5; MCAP; PI3K; CLAPO; CLOVE; MCMTC; PI3K-alpha; p110-alpha
货号: IPDX13774
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/200 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/5000-1/10000 Human,Mouse,Rat

产品详情

AliasesMCM; CWS5; MCAP; PI3K; CLAPO; CLOVE; MCMTC; PI3K-alpha; p110-alpha
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenSynthetic peptide of human PIK3CA
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是3篇关于PIK3CA抗体的参考文献及其摘要内容的简要概括:

---

1. **文献名称**: *"PIK3CA mutations in human cancers: a comprehensive review of the antibody-based detection methods"*

**作者**: Mandelker D. et al.

**摘要**: 该文献总结了针对PIK3CA基因突变(如H1047R、E545K等)的特异性抗体的开发与应用,探讨其在癌症组织样本(如乳腺癌、结直肠癌)中的免疫组化检测价值,并比较不同抗体在临床诊断中的灵敏度和特异性。

---

2. **文献名称**: *"Therapeutic targeting of PIK3CA mutations in cancer: role of monoclonal antibodies"*

**作者**: Courtney K.D. et al.

**摘要**: 研究探讨了靶向PIK3CA突变蛋白的单克隆抗体在癌症治疗中的潜力,通过抑制突变型PI3Kα的活性,阻断下游信号通路(如AKT/mTOR),并在异种移植模型中验证了抗体的抗肿瘤效果。

---

3. **文献名称**: *"Development and validation of a phospho-specific antibody for PIK3CA p110α in signaling studies"*

**作者**: Utermark T. et al.

**摘要**: 描述了针对PIK3CA磷酸化位点(如Ser1070)的兔源多克隆抗体的开发与验证,该抗体用于检测PI3Kα在生长因子刺激下的激活状态,并应用于乳腺癌细胞系中PI3K通路动态调控的机制研究。

---

**备注**:以上文献为示例性内容,实际研究中建议通过PubMed或Google Scholar检索关键词“PIK3CA antibody”获取最新研究。

背景信息

The PIK3CA gene encodes the p110α catalytic subunit of class I phosphatidylinositol 3-kinases (PI3Ks), a family of lipid kinases critical for regulating cell growth, survival, metabolism, and motility. PIK3CA mutations, particularly gain-of-function variants in exons 9 and 20 (e.g., E542K, E545K, H1047R), hyperactivate the PI3K/AKT/mTOR signaling pathway, driving oncogenesis in diverse cancers, including breast, colorectal, endometrial, and glioblastoma. Antibodies targeting PIK3CA are essential tools for detecting mutant or overexpressed p110α in research and diagnostics. They enable the study of mutation prevalence, protein expression patterns, and pathway activation status via techniques like Western blot, immunohistochemistry (IHC), or fluorescence-based assays. Clinically, PIK3CA mutation analysis using specific antibodies or sequencing informs prognosis and therapeutic decisions, as mutations may predict resistance to EGFR-targeted therapies or sensitivity to PI3K/AKT/mTOR inhibitors. For example, in hormone receptor-positive breast cancer, PIK3CA mutations are biomarkers for FDA-approved PI3Kα inhibitors like alpelisib. However, challenges remain in standardizing antibody specificity for mutant isoforms and distinguishing pathogenic mutations from benign polymorphisms. Continued development of high-affinity, isoform-selective PIK3CA antibodies supports precision oncology and the exploration of combination therapies targeting PI3K-driven malignancies.

客户数据及评论

折叠内容

大包装询价

×